Biogen: ADUHELM Continues To Reduce Underlying Pathologies Of Alzheimer’s Beyond Two Years

Biogen Inc. (BIIB) said new data showed that after nearly two and a half years of treatment (128 weeks) with ADUHELM injection 100 mg/mL for intravenous use, patients in the long-term extension phase of the phase 3 trials continued to experience significant reductions in two key Alzheimer’s disease pathologies, amyloid beta plaques and plasma p-tau181.

The company said the data from the long-term extension study showed that ADUHELM significantly reduced amyloid beta plaque levels out to Week 132. The data also showed that ADUHELM continued to decrease plasma p-tau181 levels at 128 weeks.

“These data demonstrate that long-term treatment with ADUHELM continues to reduce the underlying pathologies of Alzheimer’s disease beyond two years,” said Samantha Budd Haeberlein, SVP, Head of Neurodegeneration Development at Biogen.

Jabil Boosts FY22 Outlook – Update

While reporting preliminary, unaudited financial results for its second quarter on Wednesday, Jabil Inc. (JBL) raised its core earnings and revenue guidance for the fill-year 2022, based on strong secular tailwinds and momentum in many of its end-markets. The company also provided financial outlook for the third quarter.

For fiscal 2022, the company now projects core earnings of about $7.25 per share on revenues of about $32.6 billion. Previously, the company expected core earnings of about $6.55 per share on revenues of about $31.8 billion.

On average, analysts polled by Thomson Reuters expect the company to report earnings of $6.62 per share on revenues of $31.85 billion for the year. Analysts’ estimates typically exclude special items.

For the third quarter, the company expects earnings in a range of $1.24 to $1.64 per share and core earnings in a range of $1.40 to $1.80 per share on net revenues between $7.9 billion and $8.5 billion.

The Street is currently looking for earnings of $1.46 per share on revenues of $7.71 billion for the quarter.

With ‘Welcome to Flatch,’ Paul Feig Comes Home

Not since “Freaks and Geeks” has the director of “Bridesmaids” been so involved in a network TV show. It’s just one reason this small-town comedy felt right.

By Eric Farwell

Jabil Inc. Q2 Profit Increases, beats estimates

Jabil Inc. (JBL) announced a profit for its second quarter that increased from last year and beat the Street estimates.

The company’s bottom line came in at $222 million, or $1.51 per share. This compares with $152 million, or $0.99 per share, in last year’s second quarter.

Excluding items, Jabil Inc. reported adjusted earnings of $246 million or $1.68 per share for the period.

Analysts on average had expected the company to earn $1.47 per share, according to figures compiled by Thomson Reuters. Analysts’ estimates typically exclude special items.

The company’s revenue for the quarter rose 10.5% to $7.55 billion from $6.83 billion last year.

Jabil Inc. earnings at a glance (GAAP) :

-Earnings (Q2): $222 Mln. vs. $152 Mln. last year.
-EPS (Q2): $1.51 vs. $0.99 last year.
-Analyst Estimate: $1.47
-Revenue (Q2): $7.55 Bln vs. $6.83 Bln last year.

-Guidance:
Next quarter EPS guidance: $1.40 – $1.80
Next quarter revenue guidance: $7.9 – $8.5 Bln
Full year EPS guidance: $7.25
Full year revenue guidance: $32.6 Bln

Kyndryl Holdings Up 8% On News Of Deal With Cloudera

Shares of IT infrastructure provider Kyndryl Holdings, Inc. (KD) are rising 8 percent on Wednesday’s trading after the company announced a global partnership with Cloudera.

The partnership is expected to benefit customers by helping them enable and drive their mission-critical hybrid cloud, multi-cloud and edge computing data initiatives.

Currently at $12.28, the stock has traded between $10.92 and $32.00 during the past 52 weeks.

Karel Komarek: The £4BILLION tycoon who gambled on fall of communism

We use your sign-up to provide content in ways you’ve consented to and to improve our understanding of you. This may include adverts from us and 3rd parties based on our understanding. You can unsubscribe at any time. More info

Komarek lives in Switzerland and regards Florida as his second home. His $5.5billion (£4.2billion) fortune came from oil and gas in the Czech Republic in the 1990s, following the Velvet Revolution and the end of the communist regime.

In 2012, he took over Czech lottery firm Sazka, which he used to build a £7billion European lotteries empire. Other business ventures include IT, real estate and bio medicine.

Komarek is married to Stepanka and has four children.

When not working 12 hours a day, he enjoys golf, cycling and paddle boarding. His foundation sponsors the John F Kennedy Center for the Performing Arts in Washington DC, as well as the Dvorak Prague International Music Festival.

Herald morning quiz: March 17

Test your brains with the Herald’s morning quiz. Be sure to check back on nzherald.co.nz for the afternoon quiz.

To challenge yourself with more quizzes, CLICK HERE.